![[Photo News] Lotte's biologics bet](https://images.weserv.nl/?url=wimg.heraldcorp.com%2Fnews%2Fcms%2F2026%2F07%2F05%2Fnews-p.v1.20260705.42c32ea2a6be46069c6924585c9f0834_T1.jpg&w=3840&q=75&output=webp&we)
KRThe Korea Herald reports on Lotte Group's investment in biologics through its subsidiary Lotte Biologics. Lotte Group Chairman Shin Dong-bin visited the newly completed Plant 1 in Songdo, Incheon, emphasizing the importance of the contract development and manufacturing organization (CDMO) unit as a key growth driver for the conglomerate. The plant features eight 15,000-liter bioreactors with a combined production capacity of 120,000 liters. Shin urged rapid progress on pilot operations and validation work during the second half of the year.
Lecture du biais (Centre): The article focuses on a business-related development involving a private company's expansion plans. There is no mention of political figures, policies, or contentious issues, making the subject apolitical. The content provides factual information about Lotte Group's strategic move without any overt
Pourquoi ces scores (Factualité 75 · Objectivité 90): Factuality is moderate as the article reports on Lotte Group's biologics expansion with specific details like plant capacity and leadership statements. Objectivity is high as it presents facts without evident bias.
